Cardiovascular and renal outcomes with SGLT2 inhibitors: Real-life observational studies in older patients with type 2 diabetes
Author:
Publisher
Elsevier BV
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference67 articles.
1. 10. Cardiovascular disease and risk management: standards of care in diabetes-2023;ElSayed;Diabetes Care,2023
2. Heart failure in type 2 diabetes mellitus;Kenny;Circ Res,2019
3. KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease;Kidney Int,2022
4. Sodium-glucose co-transporter type 2 inhibitors for the treatment of type 2 diabetes mellitus;Scheen;Nature Rev Endocrinol,2020
5. SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs;Giugliano;Cardiovasc Diabetol,2021
Cited by 4 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Incidence of stroke, subsequent clinical outcomes and health care resource utilization in people with type 2 diabetes: a real-world database study in France: “INSIST” study;Cardiovascular Diabetology;2024-05-29
2. Real-life underuse of SGLT2 inhibitors for patients with type 2 diabetes at high cardiorenal risk;Diabetes Epidemiology and Management;2024-01
3. Cost‐effectiveness of canagliflozin and dapagliflozin for treatment of patients with chronic kidney disease and type 2 diabetes;Diabetes, Obesity and Metabolism;2023-07-06
4. The current role of SGLT2 inhibitors in type 2 diabetes and beyond: a narrative review;Expert Review of Endocrinology & Metabolism;2023-05-08
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3